BTK inhibitors (NTRC)

N/A

Report date: 2025/03/14 16:21:02
NME

Base Information

Drug NameBTK inhibitors (NTRC)
Drug Alias NameBTK inhibitor (NTRC)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrossfire Oncology BV
China Registration ClassN/A

Develop Information

Active CompaniesCrossfire Oncology BV
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A